Astodrimer

Summary

Astodrimer (CHEMBL2364665) is a phase-3 clinical-stage small molecule; indicated across 3 conditions including bacterial vaginosis and genital herpes.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 3 conditions

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2364665
Name	Astodrimer
Type	Small molecule
Max phase	3

Also known as: Astodrimer, Astodrimere, Astodrimero, BRI 7013, BRI-7013, BRI7013, SPL 7013, SPL-7013, SPL7013, Vivagel, ASTODRIMER

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
bacterial vaginosis	3	MONDO:0005316	EFO:0003932
genital herpes	1	MONDO:0005770	EFO:0007282
HIV infectious disease	1	MONDO:0005109	EFO:0000764

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).